Zomedica Q4 2023 GAAP EPS $(0.02), Sales $7.337M Beat $7.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
Zomedica reported Q4 2023 GAAP EPS of $(0.02) and sales of $7.337M, surpassing the $7.000M sales estimate. This represents a 19.17% increase over the previous year's sales of $6.157M.
April 01, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zomedica's Q4 2023 earnings report showed a sales increase of 19.17% YOY, beating estimates with $7.337M in sales against a $7.000M forecast.
Zomedica's better-than-expected sales figures and year-over-year growth indicate a positive performance trend, likely leading to increased investor confidence and potential short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100